Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug ProductsThe Associated PressATLANTA ATLANTA–(BUSINESS WIRE)–Jan 22, 2026– Curant Rare today ...

DFW, Great Point Partners, SK Capital and Water Street Healthcare Partners are among the PE firms investing in pharma ...

Following the FDA’s approval Monday of its muscular dystrophy drug, Cambridge, Mass.-based Sarepta Therapeutics plans to sell up to $255 million of stock and use the proceeds to fund clinical trials, ...

Rounding up five deals in the pharma commercialization segment, and delving into trends driving that activity; a discussion ...

Health tech company Waltz Health will merge with Eversana with the goal of shaking up access to prescription drugs. The deal will bring together Waltz's proprietary drug marketplaces and ...

The biotech dealmaking landscape is changing—deals are happening later in development, and securing capital is tougher than ever. For biotech companies, especially those developing precision and rare ...

Combined company offers next-generation commercialization model that directly connects life sciences to payers and patients to accelerate access, improve affordability and transform drug value across ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery ...

While the Trump administration remains unpredictable, some pharma experts are optimistic that the regulatory landscape will ...

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...

Last month, the US Food and Drug Administration (FDA) approved two new drugs and two biosimilars as well as halted commercialization for a hemophilia treatment. Here’s a deeper look of what happened ...